Join our growing community to challenge mainstream media bias and fix the news
AstraZeneca buying drug developer Alexion for $39 billion

AstraZeneca buying drug developer Alexion for $39 billion

The drugmaker AstraZeneca agreed on Saturday to buy Alexion, a biopharmaceutical company, for $39B in cash and stock, in a deal that will help the British drugmaker expand in another sector: immunology, where treatments can be highly lucrative for their makers. The boards of both firms unanimously approved the transaction. The deal is expected to close in the third quarter of 2021.

Chris
Chris
Top in Business